LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types
- Resource Type
- Abstract
- Authors
- Bono, P.; Minchom, A.; Shetty, S.; Ma, Y.T.; Cruz, R.; de Jonge, M.J.A.; Yap, C.; Pasanen, A.; Skytta, T.; Iivanainen, S.M.E.; Verlingue, L.; Jaakkola, P.; de Miguel, M.J.; Arora, S.; Graham, D.; Jalkanen, S.; Hollmen, M.; Mandelin, J.; Karvonen, M.K.; Kauko, T.; Koivunen, J.P.
- Source
- In Annals of Oncology September 2021 32 Supplement 5:S1313-S1313
- Subject
- Language
- ISSN
- 0923-7534